Jazz Pharmaceuticals plc (JAZZ) FY2026 Q2 P&L / Income Statement

Jazz Pharmaceuticals plc (JAZZ) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

1,208,300,000 US dollars

Total operating expenses

960,100,000 US dollars

Income (loss) from operations

248,200,000 US dollars

Other income (expense), net (calculated)

negative 37,200,000 US dollars

Income (loss) before income tax expense (benefit) and equity in loss of investees

211,000,000 US dollars

Income tax expense (benefit)

18,100,000 US dollars

Net income (loss)

192,800,000 US dollars

UNITED STATES

1,077,900,000 US dollars

Europe

97,400,000 US dollars

All other

33,000,000 US dollars

Cost of product sales (excluding amortization of acquired developed technologies)

116,400,000 US dollars

Selling, general and administrative

389,200,000 US dollars

Research and development

207,500,000 US dollars

Intangible asset amortization

170,000,000 US dollars

Gain on sale of priority review voucher

0 US dollars

Acquired in-process research and development

77,000,000 US dollars

Equity in loss of investees

negative 100,000 US dollars. Reported below-tax contribution to net income.

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.